Infection with multiple hepatitis C virus genotypes detected using commercial tests should be confirmed using next generation sequencing

Fernández-Caso, Belén; Fernández-Caballero, Jose Ángel; Chueca, Natalia; Rojo, Eukene; Salazar, Adolfo de; Buey, L. García; Cardeñoso, Laura; García, Féderico

doi:10.1038/s41598-019-42605-z

Cited by 11 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NGS identified novel subtypes in 9/1038 (0.9%) samples. The low frequency of recombinants and mixtures (3/1038, 0.3% each) confirms findings in the literature [15][16][17][18].…”

Section: Discussionsupporting

confidence: 90%

Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing

Bradshaw

Bibby

Manso

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…NGS identified novel subtypes in 9/1038 (0.9%) samples. The low frequency of recombinants and mixtures (3/1038, 0.3% each) confirms findings in the literature [15][16][17][18].…”

Section: Discussionsupporting

confidence: 90%

Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing

Bradshaw

Bibby

Manso

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…-Pruebas de mutaciones de resistencia a fármacos antivirales y antirretrovirales, en el campo del virus de la inmunodeficiencia humana (VIH), virus de la hepatitis C (VHC), de la hepatitis B (VHB), Citomegalovirus (CMV) o virus de la Influenza, entre otros (10,11). • Aplicaciones en bacteriología y resistencia antibiótica:…”

Section: Aplicaciones De La Secuenciación Genómica En Eeiiunclassified

SARS-CoV-2 genome sequencing in Andalusia, methodology and study of variants

et al. 2022

View full text Add to dashboard Cite

The incorporation of genomic sequencing techniques through next-generation sequencing has revolutionized clinical microbiology, innovating and improving the clinical diagnosis of infectious diseases. Today, whole genome sequencing in infectious diseases has many applications in virology, bacteriology, antibiotic resistance, epidemiology, and public health. With the appearance of SARS-CoV-2, the importance of the analysis and study of genetic sequences has been underlined. Since the initial identification of SARS-CoV-2, to date, more than 414,575 complete genomic sequences have been shared worldwide through public access databases. The ability to monitor viral evolution in near real time has a direct impact on the public health response to the COVID-19 pandemic. This paper presents the importance of genomic sequencing in microbiology, infectious diseases, epidemiology and public health, and describes how SARS-CoV-2 sequencing has been implemented in Andalusia, and what the main results are to date.

show abstract

“…HCV displays a relatively high degree of genetic heterogeneity and is classified into seven major genotypes (1–7), as well as a recently discovered genotype 8 [ 8 , 9 ]. All were identified by phylogenetic analysis of HCV strains isolated in various regions of the world.…”

Section: Introductionmentioning

confidence: 99%

Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors

et al. 2022

View full text Add to dashboard Cite

In today’s global plan to completely eradicate hepatitis C virus (HCV), the essential list of medications used for HCV treatment are direct-acting antivirals (DAAs), as interferon-sparing regimens have become the standard-of-care (SOC) treatment. HCV nonstructural protein 5A (NS5A) inhibitors are a very common component of these regimens. Food and Drug Administration (FDA)-approved NS5A inhibitors, although very potent, do not have the same potency against all eight genotypes of HCV. Therefore, this study aims to synthesize NS5A inhibitor analogues with high potency pan-genotypic activity and high metabolic stability. Starting from an NS5A inhibitor scaffold previously identified by our research group, we made several modifications. Two series of compounds were created to test the effect of changing the length and spatial conformation (para-para vs. meta-meta-positioned bis-imidazole-proline-carbamate), replacing amide groups in the linker with imidazole groups, as well as different end-cap compositions and sizes. The frontrunner inhibits genotype 1b (Con1) replicon, with an EC50 value in the picomolar range, and showed high genotypic coverage with nanomolar range EC50 values against four more genotypes. This together with its high metabolic stability (t½ > 120 min) makes it a potential preclinical candidate.

show abstract

Infection with multiple hepatitis C virus genotypes detected using commercial tests should be confirmed using next generation sequencing

Cited by 11 publications

References 35 publications

Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing

Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing

SARS-CoV-2 genome sequencing in Andalusia, methodology and study of variants

Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors

Contact Info

Product

Resources

About